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ABSTRACT: Soluble misfolded Cu/Zn superoxide dismutase (SOD1) is implicated in
motor neuron death in amyotrophic lateral sclerosis (ALS); however, the relative
toxicities of the various non-native species formed by SOD1 as it misfolds and
aggregates are unknown. Here, we demonstrate that early stages of SOD1 aggregation
involve the formation of soluble oligomers that contain an epitope specific to disease-
relevant misfolded SOD1; this epitope, recognized by the C4F6 antibody, has been
proposed as a marker of toxic species. Formation of potentially toxic oligomers is likely
to be exacerbated by an oxidizing cellular environment, as evidenced by increased
oligomerization propensity and C4F6 reactivity when oxidative modification by
glutathione is present at Cys-111. These findings suggest that soluble non-native
SOD1 oligomers, rather than native-like dimers or monomers, share structural similarity
to pathogenic misfolded species found in ALS patients and therefore represent potential
cytotoxic agents and therapeutic targets in ALS.
Accumulating evidence supports a prominent contributionof misfolding and aggregation of SOD1 to the dysfunction
and progressive death of motor neurons in ALS. Over 140
mutations (mostly missense) in the SOD1 gene have been
identified in patients with familial ALS (FALS), most of which
destabilize the native SOD1 homodimer and/or increase
aggregation propensity.1,2 Current evidence supports the
pathogenic capacity of soluble misfolded SOD1, rather than
the large insoluble aggregates that appear only near the onset of
paralysis in ALS mouse models.3−7 However, little is known
about the structural features of soluble non-native SOD1
conformers or the factors in the cellular environment that
influence misfolding and aggregation. Soluble misfolded WT
SOD1 has been found in the spinal cord from sporadic ALS
patients that do not carry mutations in SOD1,8,9 demonstrating
the sufficiency of nongenetic factors to induce the formation of
potentially toxic oligomers by SOD1.
To identify misfolded SOD1 conformers with greatest
relevance to ALS pathology, we probed isolated oligomeric
species with a conformation-specific antibody (C4F6) to
identify those with potential cytotoxicity. In FALS patients
and mouse models, C4F6 specifically recognizes soluble SOD1
found only in disease-affected tissue, revealing a connection
between FALS pathology and the as-yet unidentified epitope
bound by C4F6.7 Here, we show that higher-order non-native
oligomers of mutant SOD1, but not dimers or monomers,
contain the epitope recognized by the C4F6 antibody. To
assess the impact of the cellular redox environment on the
formation of potentially toxic soluble oligomers, we determine
the effect of a physiologically prevalent oxidative modification
(glutathionylation at Cys-111) on oligomerization. Cys-111
glutathionylation increases both the abundance of soluble
oligomers and exposure of the disease-specific epitope
recognized by C4F6, revealing a novel mechanism by which
oxidative stress modulates potentially toxic SOD1 aggregation.
Our results suggest that SOD1 acquires pathogenic features
upon the formation of soluble non-native oligomeric
assemblies, indicating a particular relevance of these species
to neuronal dysfunction in ALS.
■ EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Recombinant
SOD1 from S. cerevisiae. Mutagenesis of constructs for the
expression of human SOD1, expression in S. cerevisiae, and
SOD1 purification were performed according to previously
published methods.10,11 The final step of purification of
recombinant SOD1 is anion-exchange chromatographic sepa-
ration using a MonoQ HR 10/10 column connected to an
AKTA purifier system (GE Healthcare), which separates a
population of predominantly unmodified SOD1 from one
enriched in SOD1 that is glutathionylated at Cys-111.10
Samples were stored at −80 °C in 20 mM Tris and 150 mM
NaCl at pH 7.4 until use.
High-Resolution Mass Determination of Intact Re-
combinant SOD1. SOD1 sample buffer was exchanged with
10 mM ammonium acetate using 2 kDa VIVACON 500
filtration devices (Sartorius Stedim Biotech GmbH), after
which samples were collected by centrifugation of the inverted
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concentrator body within a fresh tube. These samples were
then diluted 1:10 in a 50% acetonitrile/49% water/1% formic
acid mixture and directly infused into the LTQ Orbitrap Velos
(Thermo Fisher Scientific) using a Picoview nanoelectrospray
source (New Objective). Spectra were collected with the
Orbitrap analyzer in positive ion mode at a resolution of 30,000
(at 400 m/z), with a maximum ion injection time of 200 ms, a
spray voltage of 5 kV, and the automatic gain control (AGC)
set to 2 × 105. Spectra were deconvoluted using Promass for
Xcalibur, version 2.5 SR-1 (Thermo Fisher Scientific).
Time-Resolved Analytical Size Exclusion Chromatog-
raphy (SEC). Cu2+ and Zn2+ were removed from as-isolated
remetalated SOD1 by dialysis against 50 mM sodium acetate
and 10 mM EDTA at pH 3.8 for 1.5 h in the case of mutant
SOD1 and 2 h in the case of the WT enzyme. Removal of
EDTA and return to physiological pH were achieved by
overnight dialysis against 20 mM Tris and 150 mM NaCl at pH
7.4. All dialysis was performed at 4 °C. Demetalated (“apo”)
SOD1 was brought to a concentration of 100 μM in 20 mM
Tris and 150 mM NaCl at pH 7.4 and incubated in a 37 °C
water bath. At each indicated time point, an aliquot containing
64 μg of apo-SOD1 was removed, filtered using a 0.22 μm
centrifugal filter, and injected onto a Superdex 200 10/300 GL
column (GE Healthcare) at 4 °C equilibrated in 20 mM Tris
and 150 mM NaCl at pH 7.4.
Estimation of Molecular Weight of Oligomers Using
Size Exclusion Chromatography Combined with Multi-
angle Light Scattering (SEC-MALS). Apo-SOD1 incubated
for 1 week under the pH, temperature, concentration, and ionic
strength conditions listed above was analyzed using a DAWN
Figure 1. Formation of metastable soluble non-native oligomers of metal-free SOD1. (A) Positions of the glutathione modification and of the FALS-
linked amino acid substitutions included in the current study; residue positions are indicated by colored spheres on the background of the WT
SOD1 crystal structure (PDB ID: 1spd). (B) SEC chromatograms showing aggregation of 100 μM apo-WT SOD1 at 37 °C in 20 mM Tris and 150
mM NaCl at pH 7.4 for up to 1 week. (C) Aggregation of 100 μM apo-SOD1 with the indicated FALS-linked amino acid substitutions under
identical conditions as those described for B. Insets show chromatograms with expanded y-axes. (D) Weight average molar masses of metastable
soluble SOD1 oligomers separated by SEC, as determined by multiangle light scattering (SEC-MALS). Black curves, absorbance at 280 nm (A280)
vs elution volume (Ve); colored curves, molecular weight (MW) calculated at each Ve from the intensities of scattered light at multiple fixed
detectors. Dashed gray lines indicate approximate theoretical molecular masses for SOD1 oligomers.
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HELEOS II light scattering instrument (Wyatt Technology),
which detects scattered light at 18 angles with respect to the
incident beam. The light scattering instrument is interfaced to
an Agilent FPLC System with a connected Superdex 200 10/
300 GL column (GE Healthcare), a T-rEX refractometer, and a
dynamic light scattering module (Wyatt Technology). SEC
separation and detection of scattered light, absorbance at 280
nm, and differential refractive index were performed at room
temperature. Data were analyzed, and weight average molar
masses as a function of elution volume were determined using
ASTRA software (Wyatt Technology) with the Zimm fit
method, which assumes weak protein−solvent interactions.12
Measurement of C4F6 Epitope Exposure of Isolated
Apo-SOD1 Oligomer Populations. Apo-SOD1 oligomers
were prepared by incubation at 100 μM in 20 mM Tris and 150
mM NaCl at pH 7.4 at 37 °C for 1 week. Samples containing
640 μg of apo-SOD1 were filtered and separated by SEC as
described above. Immediately following elution, individual
Figure 2. Cys-111 glutathionylation that occurs endogenously promotes the formation of non-native apo-SOD1 oligomers. (A) Analysis of full-
length SOD1 by mass spectrometry. For each SOD1 variant studied, deconvoluted mass spectra are shown for two populations separated by ion
exchange chromatography: one in which unmodified SOD1 is the predominant species (black spectra) and one enriched in post-translationally
modified SOD1 (red spectra). Labeled masses correspond to the average masses obtained by the deconvolution of spectra using ProMass for
Xcalibur software. Mass shifts consistent with glutathionylation (+305), irreversible oxidation (+32, +48), and phosphorylation (+80) are labeled.
Occasionally, a mass shift of +136 was observed and is consistent with SOD1 containing phosphorylation (+80), oxidation (+32), and a nonspecific
sodium adduct originating from the sample buffer (+22), all of which have been previously observed on SOD1.8,10 (B) Left, SEC chromatograms
showing populations of soluble oligomers of unmodified (black) and glutathionylated (red) apo-SOD1 incubated at 100 μM (initial dimeric
concentration) for 1 week at 37 °C in 20 mM Tris and 150 mM NaCl at pH 7.4. Right, oligomeric populations quantified by deconvolution of SEC
data and integration of Gaussian curves corresponding to individual oligomeric populations. Bar heights represent average values, and error bars
represent SD from at least 3 independent experiments. Student’s t test was used to compare the abundance of oligomers in the presence and absence
of Cys-111 glutathionylation. * = p ≤ 0.05; ** = p ≤ 0.01; *** = p ≤ 0.001.
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oligomeric populations were collected and individually loaded
onto PVDF membranes equilibrated in 20 mM Tris at pH 7.4
using a chilled Minifold I dot-blot system (S&S). Samples were
blotted in duplicate simultaneously; one blot was immediately
incubated with monoclonal antibody to misfolded SOD1
(C4F6, MediMabs) diluted 1:250 in blocking buffer (TBS-T
with 5% (w/v) nonfat dry milk); the duplicate blot was stained
with Ponceau S in 5% acetic acid to visualize total protein
loaded onto the membrane. Duplicate blotting was carried out
in lieu of fixation with Ponceau S prior to incubation with
primary antibody due to our observation of increased C4F6
reactivity following Ponceau S staining and destaining, as well
as to minimize the time elapsed between isolation of oligomers
by SEC and probing with C4F6. Blots were incubated with
C4F6 overnight at 4 °C, and C4F6 binding was visualized using
HRP-conjugated antimouse antibodies (GE Healthcare, Pierce,
Millipore). To quantify abundance of individual oligomeric
populations represented in SEC chromatograms, A280 data from
Ve = 7.5−19 mL were deconvoluted into multiple single
Gaussian distributions using Matlab (Mathworks), and the area
under each Gaussian curve was calculated as a percentage of the
total area under all Gaussian curves in the deconvoluted
chromatogram. For comparison of oligomeric populations in
glutathionylated and unmodified apo-SOD1, oligomers were
grouped based on Ve at the center of the Gaussian curve
obtained by deconvolution: O1 consists of oligomers eluting
between 14 and 15 mL, O2 consists of oligomers eluting
between 11.3 and 13.5 mL, O3 consists of oligomers eluting
between 9.2 and 11.2 mL, and Vo consists of oligomers eluting
between 8.0 and 9.0 mL (corresponding to the approximate
void volume of the column).
In Vitro Glutathionylation of SOD1. SOD1 was gluta-
thionylated in vitro by incubating at 37 °C for 30 min with
1000-fold molar excess oxidized glutathione (GSSG) in 50 mM
CAPS buffer at pH 9.7. Untreated SOD1 was subjected to the
same incubation in 50 mM CAPS buffer at pH 9.7, containing
no GSSG. Following this incubation, untreated and GSSG-
enriched SOD1 samples were demetalated as described above,
then brought to 100 μM apo-SOD1. A 64 μg aliquot was
removed, filtered using a 0.22 μm centrifugal filter, and injected
onto a Superdex 200 10/300 GL column (GE Healthcare) at 4
°C equilibrated in 20 mM Tris and 150 mM NaCl at pH 7.4.
Effect of Reducing Agent Treatment on Apo-SOD1
Oligomer Stability. Oligomers of apo-SOD1 were prepared
as described above, and DTT was added to a final
concentration of 1 mM to the sample and SEC running buffer.
Aliquots from the mixture of oligomers were separated by SEC
as described above immediately following the addition of DTT
and after 2 h and overnight incubation at room temperature.
■ RESULTS
Formation of Metastable Soluble Oligomers by Apo-
SOD1 with FALS-Linked Substitutions. To identify
potentially disease-relevant metastable SOD1 oligomers, we
incubated apo-SOD1 at physiological pH, temperature, ionic
strength, and SOD1 concentration for up to one week,
separating the reaction mixture by size exclusion chromatog-
raphy (SEC) at multiple time points. We use recombinant
protein in which SOD1’s native free cysteines (Cys-6 and Cys-
111) are retained, as they have been demonstrated to play
crucial roles in oligomerization.13,14 Metal-free (“apo”) SOD1 is
utilized in all experiments since it is widely considered to be the
common precursor to misfolded and aggregated species.4,15,16
We analyze soluble oligomers because of their particular
relevance to ALS pathology; apo-SOD1 remains soluble
throughout the 1-week incubation period, as evidenced by
the minimal changes in total A280 from SEC chromatograms
(Figure 1B,C). WT SOD1 (Figures 1B and 2B) and SOD1
containing the FALS-linked G93A and G37R substitutions
(Figure 2B) have low propensities to form soluble oligomers
under these conditions, whereas SOD1 with the A4V or I112T
substitutions shows substantial oligomerization (Figures 1C
and 2B). Analysis of SEC-separated oligomers with multiangle
light scattering is consistent with the presence of native-like
dimers, non-native-like expanded dimers, trimers, tetramers,
and hexamers (Figure 1D). The presence of an expanded dimer
is inferred from the SEC-MALS data based on the presence of a
peak eluting before the native-like dimer (indicating its larger
hydrodynamic radius), yet having a calculated molecular weight
equivalent to that of the native-like dimer (red vs cyan curves,
Figure 1D). In the case of the aggregation-prone A4V and
I112T variants, small soluble oligomers are apparent by 2 h of
incubation at 37 °C (Figure 1C) and remain detectable
throughout the 1-week incubation period. The smallest non-
native oligomers (those eluting near 13 and 14.5 mL following
injection onto the gel filtration column) increase in abundance
for the first 8−24 h, after which their populations decline
concomitant with the appearance of higher-order species
(Figure 1C).
Glutathionylation at Cys-111 Induces Monomeriza-
tion of Apo-SOD1 and Increases Propensity to Form
Non-Native Oligomers. Protein S-glutathionylation is a
reversible post-translational modification that serves, in
addition to regulatory and signaling functions, as a protective
measure against irreversible oxidation of cysteines.17 SOD1
glutathionylated at Cys-111 is abundant in SOD1 isolated from
human tissue or expressed in S. cerevisiae can be partially
resolved from the unmodified enzyme by ion-exchange
chromatography and destabi l izes the holo-SOD1
dimer.10,18−21 To assess the effects of Cys-111 glutathionylation
on the assembly of soluble SOD1 oligomers, we analyzed the
impact of this modification on the oligomeric distributions of
soluble WT and mutant apo-SOD1. For each SOD1 variant
studied, a predominantly unmodified SOD1 population and
one enriched in glutathionylated SOD1 (GS-SOD1) (Figure
2A) were incubated at physiological pH, temperature, ionic
strength, and SOD1 concentration. We assess the effect of Cys-
111 glutathionylation on oligomer formation by comparing
these two populations of recombinant human SOD1, which are
isolated by ion-exchange chromatography.10 The GS-SOD1-
enriched population contains SOD1 modified endogenously
during expression in S. cerevisiae, and only singly modified (one
glutathione moiety per monomer) SOD1 is detected. We first
analyzed this GS-SOD1-enriched fraction without further in
vitro glutathionylation to determine the effect of Cys-111
glutathionylation alone, without modification of Cys-6, Cys-57,
or Cys-146 (which are not glutathionylated in SOD1 isolated
from human tissue due to the intermolecular Cys-57-Cys-146
disulfide bond and the low solvent accessibility of Cys-610).
For the wild type as well as all FALS mutants studied,
glutathionylation of apo-SOD1 results in a significant increase
in the proportion of soluble protein present as monomers
(Figure 2B), in accordance with previous findings.10,18,21
Glutathionylation also significantly increases the abundance of
several non-native higher-order species, especially in G93A
SOD1 (Figure 2B). In all variants except A4V SOD1,
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glutathionylation significantly increases the formation of the
oligomeric population eluting just prior to the native-like
dimer: O1, the putative expanded dimer (Figures 2B and 1D).
In vitro enrichment of SOD1 with oxidized glutathione (GSSG)
recapitulates the increased abundance of apo-SOD1 monomers
and small oligomers (Figure 3); this effect was also observed for
the A4V variant, which contains a relatively low amount of
endogenously modified GS-SOD1 (Figure 2A).
Glutathionylation of SOD1 in vitro generates protein with a
single glutathione adduct, as well as species containing 2 (most
Figure 3. In vitro glutathionylation of SOD1 also promotes dimer dissociation and formation of soluble non-native oligomers. (A) Deconvoluted
mass spectra for full-length SOD1 (unenriched and treated with GSSG). Labeled masses correspond to the average masses obtained by
deconvolution of spectra using ProMass for Xcalibur software. Mass shifts corresponding to the addition of one, two, three, and four glutathione
adducts are shown at left. At right, spectra are expanded to show only the mass range corresponding to unmodified SOD1 and SOD1 containing a
single glutathione modification. (B) SEC chromatograms showing oligomeric populations of apo-SOD1 incubated in the presence or absence of
GSSG prior to demetalation, then immediately separated by SEC at 4 °C.
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likely corresponding to the modification of both free cysteines,
at positions 6 and 111) or 4 adducts (corresponding to the
modification of all cysteines in SOD1, including those at
positions 57 and 146 that participate in the native intra-
monomer disulfide bond); species with multiple glutathione
adducts were only observed for the A4V, I112T, and G93A
variants (Figure 3). In the latter case, disruption of the native
disulfide bond likely contributes to the observed misfolding and
aggregation. The increased abundance of monomeric and
oligomeric SOD1 in endogenously modified samples and in
vitro glutathionylated WT and G37R SOD1, which contain only
a single glutathione modification (Figures 2 and 3), supports
the conclusion that Cys-111 glutathionylation is predominantly
responsible for the observed promotion of dimer dissociation
and oligomerization.
Metastable Oligomers Show Enhanced Exposure of
an Epitope Common to SOD1 Found in ALS Patients.
Though soluble misfolded SOD1 (as opposed to that which is
present in insoluble aggregates) is increasingly implicated in
motor neuron dysfunction,4,5,22,23 the potential cytotoxicities of
individual oligomeric species have not been evaluated. Direct
determination of the effects of specific oligomers on motor
neuron viability is complicated by the difficulty of delivering
metastable protein assemblies to the cytoplasm of living cells.
To begin to evaluate the cytotoxic potential of the apo-SOD1
oligomers isolated by SEC, we probed for exposure of an
epitope known to be exposed on misfolded SOD1 in disease-
affected cell populations of ALS patients.7,8 The various apo-
SOD1 oligomeric populations isolated by SEC and dimeric
holo-SOD1 were bound to PVDF membranes and probed with
the C4F6 conformation-specific antibody (Figure 4). The
species with greatest reactivity to C4F6 are higher-order non-
native oligomers, those eluting at postinjection volumes ranging
from the column void to ∼14.5 mL, just prior to the elution of
native-like SOD1 dimer (Figures 2B and 4). Monomeric apo-
SOD1 is not C4F6-reactive in any of the SOD1 variants
studied, while dimeric holo- and apo-SOD1 is faintly reactive in
some cases. Oligomers of glutathionylated apo-SOD1 were also
probed with C4F6 to determine whether this modification
induces structural rearrangements that enhance exposure of the
disease-specific epitope. In the case of SOD1 with the FALS-
linked A4V or I112T substitutions, glutathionylation enhances
exposure of the C4F6-recognized epitope in higher-order
soluble oligomers (Figure 4), suggesting that glutathionylation
substantially alters the conformations of oligomers formed by
these disease-associated mutant proteins.
Cys-111 Modulates Soluble Oligomer Formation
through Mechanism(s) Independent of Intermolecular
Disulfide Bonding. The two free cysteines of SOD1,
especially Cys-111, have been recognized to modulate its
aggregation propensity.13,14 The most commonly assumed
mechanism by which free cysteines affect aggregation is their
participation in aberrant disulfide bonds, including “scrambled”
non-native intramolecular disulfide bonds and intermolecular
disulfide bonds that stabilize oligomers.24,25 However, our
findings of decreased dimer stability18 (Figure 2B) and
increased aggregation propensity (Figure 2B) in GS-SOD1
suggest that the propensity of Cys-111 to be glutathionylated
contributes to its role in SOD1 aggregation. We therefore
sought to determine whether intermolecular disulfide bonds are
required for the stability of the apo-SOD1 oligomers we
observed in vitro. Oligomers of A4V and I112T SOD1
generated by incubation at physiological pH, temperature,
ionic strength, and SOD1 concentration for one week (WT,
G93A, and G37R SOD1 form few oligomers under these
conditions (Figures 1 and 2B)) were incubated at room
temperature with the reducing agent DTT, and aliquots were
removed at various time points for SEC analysis. The largest
oligomers, those eluting from the void volume to ∼13.5 mL
postinjection on the Superdex 200 10/300 GL column, are
most sensitive to dissociation by treatment with reducing agent
(Figure 5). While the abundance of these oligomers decreases
steadily following the addition of DTT, the oligomeric
population eluting at ∼14.5 mL (O1) is relatively stable in
the presence of the reducing agent (in A4V, O1 abundance
remains largely unchanged for at least 2 h following the
introduction of DTT; in I112T, O1 abundance increases in the
presence of DTT (Figure 5)). The relative resistance of the O1
population to dissociation by DTT indicates that the stability of
these oligomers is less dependent on the presence of
intermolecular disulfide bonds or that any intermolecular
disulfide bonds present are not sufficiently solvent-exposed to
Figure 4. Non-native oligomers of SOD1 are potentially toxic in ALS.
Dot blots of apo-SOD1 oligomers isolated by SEC and probed with
the C4F6 monoclonal conformation-specific antibody, which has been
proposed to recognize a toxic subset of misfolded SOD1.7 Dimeric
SOD1 isolated from S. cerevisiae and remetalated (“holo”) was also
probed to determine initial C4F6 reactivity prior to the removal of
metals and oligomerization. The amounts of each oligomeric
population bound to the membrane were visualized by Ponceau S
staining.
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be reduced by DTT added to the buffer. The increase in O1
abundance in I112T may be attributed to both continual
accumulation of this oligomer throughout the period of
incubation with DTT or the generation of oligomers of this
size upon dissociation of larger oligomers.
■ DISCUSSION
Relevance of the in Vitro System to Pathological
SOD1 Aggregation in ALS. Although misfolding and
aggregation of SOD1 is believed to be a major contributor to
ALS pathology, little is known about the potential toxicities of
individual aggregate species or the cellular determinants of their
formation. Here, we examine the propensities of WT and FALS
mutant SOD1 to form metastable soluble oligomers with an
epitope linked to toxicity in ALS and explore the effects of
oxidative modification of Cys-111, a residue known to
modulate SOD1 aggregation. We assess oligomerization of
SOD1 under conditions approximating physiological pH (7.4),
temperature (37 °C), and SOD1 concentration (100 μM,24)
without agitation. The degrees to which the various FALS-
linked mutations increase SOD1 destabilization and aggrega-
tion propensity have been shown to be correlated with disease
severity.2 Although this correlation was recently challenged,26
this latter study employed the use of SOD1 in which both free
cysteines (at positions 6 and 111) are mutated to alanine and
serine, respectively, potentially restricting the applicability to
physiological SOD1 aggregation. We find that the A4V and
I112T substitutions, which are found in patients with rapidly
progressing FALS,2 exhibit the highest propensities to form
soluble oligomers (Figures 1C and 2B). These results would be
predicted by the correlation of aggregation propensity with
disease severity, as would the minimal aggregation of SOD1
containing the G37R substitution (Figure 2B), which causes
relatively slowly progressing paralysis in ALS patients and
mouse models.2,27 The higher oligomerization propensities of
the A4V and I112T variants may stem from the proximity of
these substitutions to the native homodimeric interface (Figure
1A).
Identification of Species with Potential Toxicity in
ALS. While we observe differences in aggregation propensities
among the SOD1 variants studied, the formation of certain
metastable non-native oligomers (such as those eluting at 14.5
mL) by both wild type and FALS mutant SOD1 suggests that
some common mechanism(s) underlie SOD1 oligomerization.
To explore potentially unifying conformational changes that
occur as apo-SOD1 transitions from dimeric to monomeric and
higher-order oligomeric species, we analyzed the exposure of a
putatively disease-relevant epitope. The epitope recognized by
C4F6 is not known, but this antibody binds to soluble
misfolded SOD1 in disease-affected motor neuron populations
in ALS patient spinal cord.7,8 For this reason, the C4F6
monoclonal antibody has been proposed to recognize an
epitope present specifically in toxic conformers of SOD1.7 We
find that the C4F6 antibody binds to several higher-order
oligomers of apo-SOD1 but not to monomers and rarely to
native-like dimers (Figure 4). The C4F6 antibody was raised
against apo-G93A and has been shown to have specific
reactivity to this sequence element (WT SOD1, FALS mutants
other than G93A, and SOD1 with other substitutions other
than alanine at position 93 show little reactivity to C4F6 when
denatured).8,27 However, C4F6 also exhibits conformation-
specific reactivity, which is not restricted to G93A under
Figure 5. Intermolecular disulfide bonding is not universally required for the persistence of metastable non-native oligomers in vitro. (A) Apo-SOD1
oligomers generated by incubation for 1 week at 37 °C in 20 mM Tris and 150 mM NaCl at pH 7.4 were separated by SEC in the absence (black
curves) of DTT and in the presence of 1 mM DTT following incubation at room temperature (red curves). Designations of oligomeric populations
(D, M, O1, O2, O3, and V0) correspond to those in Figure 2A, while M* denotes a species that that appears subsequent to DTT treatment and
whose elution volume is consistent with an expanded monomer. (B) Quantification of oligomeric populations prior to DTT treatment and after
room temperature incubation with 1 mM DTT for the indicated time periods. ON = overnight incubation.
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nondenaturing conditions.8 We probe apo-SOD1 oligomers
under nondenaturing conditions in order to detect species with
the conformation-specific epitope recognized by C4F6 in ALS-
affected motor neurons. The strong C4F6 reactivity of
unmodified apo-G93A oligomers may partially be due to the
recognition of the G93A sequence epitope. Previous work has
implicated soluble misfolded SOD1 in a range of oligomeric
states in specific cytotoxic phenomena;5,22,23 our findings
suggest that, of the pool of soluble species formed by apo-
SOD1 in vitro, metastable oligomers larger than the native
dimer are the most likely toxic culprits.
Oxidative Modification of Cys-111 Induces Conforma-
tional Changes That Promote Oligomer Assembly and
Exposure of the Disease-Linked C4F6 Epitope. Oxidation
of SOD1 has been shown to induce its misfolding and
aggregation,8,28,29 and various oxidized forms of SOD1 have
been linked to toxicity in cultured neurons,30 a mouse model of
FALS,31 and a subset of sporadic ALS cases.32 In particular, the
presence of an oxidizable cysteine at position 111 has been
shown to promote SOD1 aggregation,13,29 an effect that has
been widely attributed to the stabilization of insoluble
aggregates and soluble oligomers by intermolecular disulfide
bonds involving Cys-111.14,24,31,33 However, others have
suggested that intermolecular disulfide cross-linking is a
secondary event to non-native oligomer assembly and is not
universally present in SOD1 oligomers.34,35
We find that glutathionylation of Cys-111, a reversible
oxidative modification present extensively on SOD1 from
human tissue,10,20,36,37 increases the proportion of monomeric
apo-SOD1 in all studied variants and enhances the formation of
several soluble non-native oligomers (Figure 2B). This
observation, as well as the increased C4F6 reactivity of GS-
I112T-SOD1 and GS-A4V-SOD1 oligomers (Figure 4),
suggests that conformational changes in SOD1 induced by
Cys-111 glutathionylation18,19 have significant effects on the
abundance and morphologies of SOD1 oligomers. In particular,
the altered morphologies of GS-SOD1 oligomers suggest that
glutathionylation induces substantial conformational change(s)
not limited to those which result in a weakened dimer interface.
That is, rather than simply increasing the population of
monomers available to oligomerize, glutathionylation alters the
structural features of oligomers themselves. The alteration of
oligomer structure induced by this modification is particularly
notable since it increases exposure of an epitope linked to
toxicity in ALS. We also find that while intermolecular disulfide
bonds stabilize higher-order soluble SOD1 oligomers, these
bonds are absent or not essential for stability in the smallest and
earliest-appearing non-native oligomers (the O1 population,
Figure 5).
Taken together, these results suggest that intermolecular
disulfide cross-linking represents just one mechanism by which
Cys-111 facilitates oligomerization. At the earliest stages of
SOD1 misfolding and aggregation, oxidative modification of
Cys-111 induces conformational changes that destabilize the
dimer18,19 and favor assembly into potentially toxic non-native
oligomers (Figures 2B and 4). Given the central role of Cys-
111 in SOD1 aggregation 13 and the abundance of
glutathionylated SOD1 in human tissue,10 we hypothesize
that Cys-111 glutathionylation is a physiologically relevant
mechanism by which oxidative stress induces aberrant
oligomerization of SOD1.
Overall, our results highlight the toxic potential of soluble
oligomers of apo-SOD1 and demonstrate the ability of Cys-111
oxidation to promote the formation of oligomers with the
disease-linked epitope. The latter finding implicates oxidative
stress as a factor in the cellular environment that can induce the
formation of potentially toxic SOD1 oligomers. Our use of
C4F6 binding as a proxy for disease relevance is, to the best of
our knowledge, the first evaluation of the potential toxicities of
SOD1 oligomers isolated in vitro. Enhanced exposure of the
disease-linked epitope in non-native SOD1 oligomers supports
a cytotoxic role for these assemblies, in parallel with previous
findings directly demonstrating the toxicity of small oligomers
of Aβ and α-synuclein in models of Alzheimer’s disease and
Parkinson’s disease, respectively.38,39 A pattern is thus emerging
among numerous neurodegenerative disorders in which small
oligomers exert neurotoxic effects that are mitigated by
assembly into large, insoluble species such as amyloid
fibrils.40,41 Inhibition of small oligomer formation of disease-
linked proteins therefore represents a therapeutic approach
with potentially broad applicability to many neurodegenerative
disorders. Knowledge of atomic-level structural features of
putatively toxic soluble SOD1 oligomers and identification of
factors modulating their formation would facilitate the direct
determination of their contribution(s) to cellular pathology, as
well as provide an avenue for the development of
antioligomerization therapeutics for ALS.
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